Facebook
X
LinkedIn
Forward
Establishing Collaborative Practices Between Community Providers and Specialty Centers to Improve Diagnosis and Treatment of Fibrosing ILDs
Ann Arbor, MI US
September 17, 2025
University of Michigan-Brarwood Health Associates
Fibrosing interstitial lung diseases (ILDs), encompassing a range of disorders such as idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF), and systemic autoimmune rheumatic disease-associated ILD (SARD-ILD), are rare diseases with symptoms that often overlap with other respiratory ailments, making it difficult to identify and diagnose. Early diagnosis of ILD is crucial to ensure timely treatment initiation, potentially slowing disease progression and improving patient outcomes, quality of life, and even survival. The Pulmonary Fibrosis Foundation Care Center Network (PFF-CCN) provides expertise in the diagnosis and management of ILDs and studies have found that initial management in specialized ILD centers is associated with improved mortality and lower all-cause hospitalizations; however, most centers are in urban areas.
Fibrosing interstitial lung diseases (ILDs), encompassing a range of disorders such as idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF), and systemic autoimmune rheumatic disease-associated ILD (SARD-ILD), are rare diseases with symptoms that often overlap with other respiratory ailments, making it difficult to identify and diagnose. Early diagnosis of ILD is crucial to ensure timely treatment initiation, potentially slowing disease progression and improving patient outcomes, quality of life, and even survival. The Pulmonary Fibrosis Foundation Care Center Network (PFF-CCN) provides expertise in the diagnosis and management of ILDs and studies have found that initial management in specialized ILD centers is associated with improved mortality and lower all-cause hospitalizations; however, most centers are in urban areas.
In collaboration with an ILD expert, pulmonology and rheumatology leaders will facilitate a 1-hour learning and action planning program with their clinical teams to adopt effective monitoring, diagnostic, and referral practices to a recognized ILD center for their high-risk patients; and improve local, ongoing coordination of care practices.
Educational Partner: Academy for Continued Healthcare Learning (ACHL)
Commercial Support: This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Commercial Support: This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Target Audience
This educational activity is designed for rheumatologists, pulmonologists, APPs in these settings and other members of the multidisciplinary team who manage patients with fibrosing ILD.
Learning Objectives
Upon completion of this activity, learners will be able to:
- Discuss the social and psychological burdens associated with fibrosing interstitial lung diseases (ILDs);
- Apply evidence-based guidelines for the interpretation of diagnostic tools, such as pulmonary function tests (PFTs) and high-resolution computed tomography (HRCT), in the evaluation of fibrosing ILDs;
- Evaluate current and emerging antifibrotic therapies for idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF), and systemic autoimmune rheumatic disease-associated ILD (SARD-ILD) in terms of efficacy, adverse events (AEs), and patient suitability;
- Design patient-centered care plans that integrate current and emerging pharmacologic interventions to alleviate the clinical burden associated with fibrosing ILDs;
- Outline effective strategies for interdisciplinary collaboration in the management of fibrosing ILDs, with a focus on coordinated care among pulmonologists and rheumatologists.
You may also be interested in
University of Michigan-Brarwood Health Associates
325 Briarwood Cir
Ann Arbor, MI
48108
United States
WANT TO KNOW MORE?
Visit the Academy for Continued Healthcare Learning (ACHL) website!
ACCESSIBILITY The University of Chicago is committed to providing equal access appropriate to need and circumstances and complies fully with legal requirements of the Americans with Disabilities Act. If you are in need of special accommodation, please contact our office at https://www.achlcme.org/.
The University of Chicago reserves the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, The University of Chicago is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.
FACULTY
Ayodeji Adegunsoye, MD, PhD
Assistant Professor, Department of Medicine
Scientific Director of ILD Program, Department of Medicine, Pulmonary & Critical Care Medicine
University of Chicago
Chicago, IL
Assistant Professor, Department of Medicine
Scientific Director of ILD Program, Department of Medicine, Pulmonary & Critical Care Medicine
University of Chicago
Chicago, IL
Elizabeth Volkmann, MD, MS
Associate Professor, Medicine (Rheumatology)
UCLA
Los Angeles, CA
Associate Professor, Medicine (Rheumatology)
UCLA
Los Angeles, CA
Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School Of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.
REGISTRATION: For more information, visit the ACHL website or click the button below!
Please login or create an account to proceed.